1 |
Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto MR, Barcons S, Guirao X, Albert L, Cano A, Pareja R, Caixàs A, Rigla M. Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism. J Endocrinol Invest 2023;46:829-40. [PMID: 36334246 DOI: 10.1007/s40618-022-01948-7] [Reference Citation Analysis]
|
2 |
Armeni E, Grossman A. The Spectrum of Familial Pituitary Neuroendocrine Tumors. Endocr Pathol 2023;34:57-78. [PMID: 36401106 DOI: 10.1007/s12022-022-09742-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A, Friedman E, Bernstein-Molho R, Tirosh A. Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 2023;30:e220174. [PMID: 36256846 DOI: 10.1530/ERC-22-0174] [Reference Citation Analysis]
|
4 |
Gokozan HN, Scognamiglio T. Advances and Updates in Parathyroid Pathology. Adv Anat Pathol 2023;30:24-33. [PMID: 36315270 DOI: 10.1097/PAP.0000000000000379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Ababneh E, Nosé V. The Classic, the Trendy, and the Refashioned: A Primer for Pathologists on What Is New in Familial Endocrine Tumor Syndromes. Adv Anat Pathol 2023;30:69-78. [PMID: 36136401 DOI: 10.1097/PAP.0000000000000370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
6 |
Singeisen H, Renzulli MM, Pavlicek V, Probst P, Hauswirth F, Muller MK, Adamczyk M, Weber A, Kaderli RM, Renzulli P. Multiple endocrine neoplasia type 4: a new member of the MEN family. Endocr Connect 2023;12:e220411. [PMID: 36520683 DOI: 10.1530/EC-22-0411] [Reference Citation Analysis]
|
7 |
Inder WJ, Jang C. Treatment of Prolactinoma. Medicina (Kaunas) 2022;58:1095. [PMID: 36013562 DOI: 10.3390/medicina58081095] [Reference Citation Analysis]
|